Bio-Rad Laboratories, Inc.

AI-generated fair value estimate for this company.

Method: Same 10-year unlevered FCF DCF as the Class A shares (ticker BIO): $370M normalized FCF base; 5% growth years 1-5, 3% years 6-10; 8% discount rate; 3% terminal growth; ~$250M net cash; 26.74M total combined shares.

Reasoning: Bio-Rad's Class A and Class B common stock represent the same underlying economic claim on the company's earnings and assets (Class B carries additional voting rights but the same dividend/economic entitlement per share), so the intrinsic value per share computed from the consolidated company DCF applies equally to both share classes rather than requiring a separate standalone valuation.